FDA Targets Acetaminophen Safety Evaluation In Plan To Mine OTC Use Data
This article was originally published in The Pink Sheet Daily
Executive Summary
An RFP to provide FDA with direct access to data on consumers’ OTC use identifies the public health impact of potential changes in dosing information on acetaminophen product labels as one reason for the planned data evaluation. Access to the data also will increase FDA’s ability to perform regulatory impact studies, particularly to assess the impact of Rx-to-OTC switches.
You may also be interested in...
In Brief: FDA responds to Nasacort suit, acts on acetaminophen and continues medical food enforcement
FDA responds to Nasacort Allergy suit; FDA will act on lower acetaminophen dose; FDA warns consumers about wart removers; FDA continues medical food enforcement; Supplements must include declared ingredients; CHPA applauds DXM-related legislation; and USP opens Shanghai facility.
Lower Acetaminophen Doses Recommended Despite Cost Impact, Lack Of Data
A joint advisory committee recommended as a "top priority" that FDA lower the maximum single and daily dose of acetaminophen, despite inconclusive data that the current dose poses significant hepatotoxicity risks
Abbott's ‘Bedrock Of Good Health’ Nutritionals Business Faces Mounting Infant Formula Litigation
Nutritional product business had 5.1% Q1 sales growth and is like Abbott’s other segments, “super well-aligned to the global demographics and trends in health care,” says CEO Ford. But as it defends complaints of damages from powder formulas made at facility found with unsafe levels of bacterial contaminants, Abbott’s also targeted in litigation alleging failure to warn about risk of infants born prematurely developing necrotizing enterocolitis if fed cow’s milk-based formula.